Buradasınız

Anasayfa » Content

RADYOTERAPİ VE KEMOTERAPİ GÖREN HASTALARDA ORAL BAKIM

ORAL HEALTH CARE IN PATIENTS UNDERWENT CHEMOTHERAPY AND RADIOTHERAPY

Journal Name:

  • Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi

Publication Year:

  • 2006

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Chemotherapy and radiotherapy are common used in the treatment of malignant diseases. The aim of these therapies is to eradicate the neoplastic cell that is capable of multiplying rapidly. However, these therapy techniques may to cause damage the tissues, including oral mucosa, salivary glands, orofacial blood vessels and bone marrow. Orofacial complications can be seen commonly after radiotherapy to the head and neck and after chemotherapy. At this paper, oral care was taken in to consideration by explaining complication occurred patients that undergo chemotherapy and radiotherapy.
Bookmark/Search this post with
Abstract (Original Language): 
Malign hastahkaarın tedavisinde kemoterapi ve radyoterapi yaygın olarak kullanı/ır. Bu tedavilerin amacı hızaa çoğalabilen neoplazik hücreyi ortadan kadrrmaktrr. Ancak bu tedavi şekilleri oral mukoza dokUarını, tükürük bezlerini, orofasiyal kan damariarını ve kemik iliğini hasara uğratabilir. Orofasiyal kompiikasyon/ar; kemoterapi sonrası ve baş boyun radyoterapisini takiben yaygın olarak karşımıza çıkar. Bu makale de radyoterapi ve kemoterapi gören hastalarda oluşan kompiikasyon/ar anlatılarak oral bakımın önemi vurgulandı.
FULL TEXT (PDF): 
PDF icon arastirmax-radyoterapi-kemoterapi-goren-hastalarda-oral-bakim.pdf
  • 3
50-55
  • Turkish

REFERENCES

References: 

1. Shaw M.J, Kumar N.D.K, Duggal M, Fiske J, Lewis D.A, Kinsel/a T, Nisbet T. Oral management of patients following oncology treatment: literature-review. British Journal Of Oral&Maxillofacial Surgery 2000; 38: 519 - 524
2. Sculy C, Epstein J.B. Oral Heatth Care for the Cancer Patient: Reviews. Oral Oncol, Eur J Cancer 1996; 32B: 281 - 92
3. Joyston-Bechal S, Hayes K, Davenport ES, Hardie JM. Caries incidence, mutans streptococci and lactobaciiii in irradiated patients during a 12 month preventive programme using chlorhexidnne and fluoride. Caries Res 1992; 26:384-390
4. Lockhart PB, Clarke J. Pre-therapy dental status of patients with malignant conditions of the head and neck. Oral Surg Oral Med Oral Pathol 1994; 77:236-241
5. Epstein JB, McBride GC, Stevenson-Moore P, Merilees H, Spinelli J. The efficacy of chlorhexidnne gel nn reduction of Streptococcus mutans and Lactobacillus species nn patients treated with radiation therapy. Oral Surg Oral Med Oral Pathol 1991; 71:172-178
ÇAKUR, MİLO+LU, HARORLI
6.
Harorh
A, Y/maz AB, Akgul H.M. Rayolojide Temel Kavramlar ve Radyodiagnostik. Erzurum: Ata. Uni. Zrraat Fak. Ofset Tesiseeri, 2001; 45-55
7.
Çankaya
H. Kemoterapi Sonucu Göz/enen Oral Değişiktik/er ve Tedavi Yaklaşım/arı. E. ÜÜ. Diş Hek. Fak. Derg. 2001; 22:103-108
8. Barker G, Loftus L, Cuddy P, Baker B. The effects of sucralfate suspension on radiotherapy induced mucosttis. Oral Surg Oral Med Oral Pathol 1991; 71:288-293
9. Franzen L, Henrkksson R, Ltttbrand B, Zackrisson B. Effects of sucralfate on mucositis during and following radiotherapy of malignancies in the head and neck region. A double-blind p/acebo-contro/eedstudy.Acta Oncol1995; 34:219-223
10. Spjkervet FKL, Saene HKF van, Panders AK et al. Effect of chlorhexidnne rinsing on the oropharyngeal ecology in patients with head and neck cancer who have rrradaaton mucosttis. Oral Surg Oral Med Oral Pathol1989; 67:154-161.
11. Epstein JB, Stevenson-Moore P. Benzydamine hydrochloride nn prevention and management of pain in oral mucositis associated with radiation therapy. Int J Radaat Oncol Bio Phys 1986; 62: 145-148
12. Wadeeggh RG, Redman RS, Graham ML. Vttamnn E nn the treatment of chemotherapy-induced mucosttis. Am J.Med 1992; 92: 481-484.
13. Ciasis G, Namer M, Schneider M. Laser therapy nn the prevention and treatment of mucosttis caused by anticancer chemotherapy. Bull Cancer Paris 1992; 79:183-191
14. Joseph A. Regezi, James J. Scıubba, Richard C.K. Jordan. Oral Pathology. Saunders. USA 2003:76¬79
15. Thomas CJ, Nutt GM. The in vitro fungicidal properties of Viscogel alone and combined with Nystatin and Amphotericin B. Oral Rehab 1978; 5:167-172
16. Meunier F, Paesmans M, Autier P. Value of antifungal prophylaxis with antifungal drugs againist oropharyngeal candidiasis in cancer patients. Oral Onco,Eur J Cancer 30B,196-199
17. Barkvol P, Attramadal A. Effect of nystatin and chlorhexidnne dig/uconate on Candida albicans. Oral Surg Oral Med Oral Pathol 1989;67:279-281
54
Atatürk Üniv. Diş Hek. Fak. Derg.
Cilt: 16, Sayı: 3, Yıl: 2006, Sayfa: 50-55
18. Stephen LC, Schutthesiss TE, Price RE, Ang KK, Peters LI. Radiation apoptosis of serous acinar cells of salivary and aacrimal glands. Cancer 1991; 67:1539-1543
19. Mrra JG, Fu/erton GD, Wescott WB. Correlation between initial saiivary flow rate and radiation dose in the production of xerostomaaActa Radiol Oncol 1982; 21:151-154
20. Shum CA, Izutsu KT, Mo/bo DM et al. Changes nn saiivary buffer capacity in patients undergoing cancer chemotherapy.J Oral Med1979; 34:76-80
21. Robert AO, Blanchaert R. Current management of oral cancer: A muttidiscipinnary approach. JADA 2001; 32:19 -23
22. Herod EL. The use of milk as a saiiva substitute. J Pubic Heatth Dent 1994;54:184-189
23. Risheim H, Amegerg P. Saiivary stmuaaton by chewing gum and lozenges nn rheumatic patients wtth xerostomia.Scand J Dent Res 1993;101:40-43
24. Fox PC, Atkinson JC, Macynsk AAA et al. Pilocarpine treatment of saiivary gland hypofunction and dry mouth(xerostomaa). Arch Intern Med 1991; 151:1149-1152
25. Epstein JB, Burchill JL, Emerton S, Le N,Si/verman SJr. A clinical trial of bethanechol in patients wtth xerostomia after radiation therapy a pilot study. Oral Surg Oral Med Oral Pathol 1994; 77: 610¬614
26. Epstein J, Stevenson-Moore P.A. Clinical comparative trial of saiiva substitutes in radiation-induced salivary gland hypofunction.Spec Care Dent 1992112:21-23
27. Visch LL, S'Gravenmade EJ; Schraub RM et al. A double binnd crossover trial of CMC- and mucin-contannnng saiiva substitutes. Int J Oral Maxi/ofac Surg 1986; 15:395-400
28. Epstein JB, Schubert MM. Management of orofacial pain in cancer patients.Oral Onco,Eur J Cancer 1993; 29B: 243-250
29. Berger A, Henderson M, Nadoolman W et a I. Oral capsaicin provides temporary retef for oral mucositic pain secondary to chemotherapy/ radiation therapy. J Pain Symptom Manag 1995110:243-248
30. Mossman KL, Henknn RI Radiation-induced changes in taste acuity in cancer patients. Int J Radaat Oncol Phys 1978; 4: 663-670
ÇAKUR, MİLO+LU, HARORLI
31. Brunello DL, Mandkkos MN. The use of a dynamic opening device in the treatment of radiation induced trismus.Aust Prosthodont J 1995; 9: 45¬48
32. Lockhart PB, Clark J. Pretherapy dental status of patients wtth malignant conditions of the head and neck. Oral Surg 1994; 77:236-241
33. Feber T. Mouth care for patients receiving oral rrradiation. Professional Nurse 1995;10: 666-670
34. Scully C, Flint S, Porter SR. Oral diseases. London: Martin Dunttz, 1996; 198.
35. Kluth EV, Jain PR, Struhel RN, Frich JC. A study of factors contributing to development of osteoradionecrosis of the jaws. J Prosth Dent 1988; 59:194-201
36. McKenzze MR, Wong FLW, Epstein JB, Lepawsky M. Hyperbaric oxygen and postradiation osteonecrosis of the mandible. Oral Oncol, Eur J Cancer 1993; 29B: 201-207
37. King GE, Scheetz J,Jacob RF et al. Electrotherapy and hyperbaric oxygenpromising treatments for post-radiation complications. J Prosthet Dent 1989; 62:331-334
38. Harris M. The conservative management of osteoradionecrosis of the mandible wtth uttrasound therapy. Br J Oral Maxiilofac Surg 1992; 30:313-318
39. Reher P, Doan N, Bradnock B, Meghji S, Haris M. Therapeutic uttrasound for osteoradionecrosis: an nn vitro comparison between 1 MHz and 45 kHz machines. Eur J Cancer 1998; 34:1962-1968

Thank you for copying data from http://www.arastirmax.com